Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.

"Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)"